Antibody-drug Conjugate

Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) that specifically targets the epidermal growth factor receptor (EGFR). This reagent exhibits potent antitumor activity and is valuable for research applications involving glioma, head and neck squamous cell carcinoma, non-small cell lung cancer, epidermoid carcinoma of the skin, and squamous cell carcinoma of the tongue. Its mechanism of action combines selective targeting of EGFR with cytotoxic delivery, making it a significant tool in cancer research and therapeutic studies.

Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate that targets HER2, featuring a potent payload linked to a STING agonist. This innovative design promotes immune activation, enhancing anticancer efficacy. Its applications are particularly relevant in the development of targeted therapies for HER2-positive cancers, making it a valuable tool for cancer research.

Trastuzumab emtansine is an antibody-drug conjugate (ADC) that combines the HER2-targeting capabilities of trastuzumab with the cytotoxic effects of the microtubule-inhibitory agent DM1. This compound demonstrates potent antitumor activity and is particularly relevant in the study of advanced breast cancer. Its dual mechanism allows for targeted delivery of cytotoxic agents, making it a valuable tool in oncological research and therapeutic development.

Disitamab vedotin is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). This reagent consists of a monoclonal antibody linked through a cleavable connector to the cytotoxic drug Monomethyl auristatin E (MMAE). Disitamab vedotin is designed to enhance antitumor immunity and is applicable in cancer research, particularly in studies focused on HER2-positive malignancies.

Loncastuximab tesirine is an antibody-drug conjugate (ADC) targeting the cluster of differentiation 19 (CD19) antigen. This compound comprises the Loncastuximab antibody linked to Tesirine, a potent cytotoxic agent. Upon binding to CD19, Loncastuximab tesirine is internalized, leading to apoptosis in malignant B-cells. This reagent is primarily utilized in research focused on diffuse large B-cell lymphoma and related hematological malignancies.

HE-S2 is an antibody-drug conjugate that targets the PD-1/PD-L1 interaction, thereby enhancing antitumor immune responses. By activating the Toll-like receptor 7/8 (TLR7/8) signaling pathway, HE-S2 exhibits significant antitumor activity. This reagent is suitable for research applications involving cancer immunotherapy and the modulation of immune responses in tumor microenvironments.

(R)-DM4-SPDP is a conjugate consisting of the linker SPDP and the cytotoxic agent DM4, specifically designed for the development of antibody-drug conjugates (ADCs). This compound facilitates targeted delivery of therapeutic agents to tumor cells, enhancing the efficacy of cancer treatment while minimizing systemic toxicity. (R)-DM4-SPDP is ideal for research applications focused on ADC design and optimization in oncology studies.

Rolinsatamab talirine is an antibody-drug conjugate (ADC) designed to target the prolactin receptor (PRLR). This compound combines rolinsatamab with an enzymatically cleavable peptide linker and SGD-1882, facilitating targeted drug delivery to cells expressing the PRLR. Rolinsatamab talirine exhibits potent biological activity, making it suitable for research applications in cancer therapeutics and receptor-targeted drug development.

Ifinatamab deruxtecan is an antibody-drug conjugate that targets B7-H3, linking an anti-B7-H3 antibody to the DNA topoisomerase I inhibitor DXd. This compound exhibits significant antitumor activity, making it a valuable tool for research in oncology. It is particularly relevant for studies focused on targeted delivery of therapeutic agents in cancer treatment.

Tisotumab vedotin is an antibody-drug conjugate (ADC) that targets tissue factor (TF). This compound is designed by covalently linking a fully human monoclonal antibody (TF-011) to the microtubule disruptor Monomethyll Auristatin E (MMAE) through the VcMMAE linker. Tisotumab vedotin exhibits immunomodulatory and anti-tumor activities, making it a valuable tool for researching advanced or metastatic solid tumors, including cervical cancer.

Farletuzumab ecteribulin is an antibody-drug conjugate (ADC) that targets the folate receptor alpha (FRA) using the humanized anti-FRA antibody Farletuzumab. Conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin, this compound features an agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin exhibits significant cytotoxicity towards FRA-positive cancer cells and demonstrates potent antitumor activity, making it a valuable reagent for research in targeted cancer therapies.